Dr. Li Gan

A rare gene mutation that delays Alzheimer’s disease does so by damping inflammatory signaling in brain-resident immune cells, according to a preclinical study led by investigators at Weill Cornell Medicine. 

At the 12th annual Helen and Robert Appel Alzheimer’s Disease Research Institute Symposium, scientists and clinicians shared their latest research which is advancing how Alzheimer’s disease is diagnosed and treated. 

Inhibiting an immune signaling protein called TLR7 may help preserve the protective layer surrounding nerve fibers in the brain during both Alzheimer’s disease and ordinary aging, suggests a study led by researchers at Weill Cornell Medicine.

Weill Cornell Medicine investigators have found that two genetic variants that confer high risk of Alzheimer’s disease (AD) together trigger a harmful inflammatory response in the brain’s immune cells, particularly in females, in a preclinical model.

Weill Cornell Medicine’s Celebration of Diversity, part of the institution’s sixth annual Diversity Week, was held on April 15. The awardees were honored for their commitment to diversity and inclusivity in academic medicine through exemplary contributions in mentorship, research, clinical care, community service and advocacy.

Weill Cornell Medicine scientists have developed an innovative human neuron model that robustly simulates the spread of tau protein aggregates in the brain—a process that drives cognitive decline in Alzheimer's disease and frontotemporal dementia. 

The 11th annual Appel Alzheimer's Disease Research Institute Symposium brought together leading scientists and clinicians in the field to present the latest advances in understanding Alzheimer’s and related neurodegenerative diseases. 

Targeting part of an antiviral pathway triggered by the accumulation of a key pathogen shared in Alzheimer’s disease and frontotemporal dementia may one day offer a new therapeutic approach to deterring or delaying cognitive decline.

The 10th annual Appel Alzheimer's Disease Research Institute Symposium brought fascinating reports of progress in understanding Alzheimer’s and related neurodegenerative diseases.

The discovery of how to shift damaged brain cells from a diseased state into a healthy one poses a new potential path to treating Alzheimer’s and other forms of dementia.

Inhibiting an important signaling pathway in brain-resident immune cells may calm brain inflammation and thereby slow the disease process in Alzheimer’s and some other neurodegenerative diseases, suggests a study by Weill Cornell Medicine investigators.

By mapping all the protein interactions of a dementia-linked protein in the brain called Tau, a team of Weill Cornell Medicine investigators has created a road map for identifying potential new treatment targets for Alzheimer’s disease and related dementia.

A gene mutation linked to Alzheimer’s disease alters a signaling pathway in certain immune cells of individuals with the disease, according to a new study by scientists at Weill Cornell Medicine.

Some of the latest research discoveries in neurodegenerative disease and their potential therapeutic applications were featured at the ninth annual Appel Alzheimer's Disease Research Institute Symposium, held remotely on Nov. 9. 

Weill Cornell Medicine neuroscientist Dr. Li Gan is driving toward one of the most coveted medical breakthroughs: an effective treatment for Alzheimer’s disease.

Investigators on the forefront of research into neurodegenerative disorders shared some of their latest discoveries and possible implications for treatment at the eighth annual Appel Alzheimer's Disease Research Institute Symposium, held remotely on Oct. 14.

Immune cell activity in the brain differs between males and females in ways that may explain why some neurodegenerative diseases affect the sexes differently

In the roughly 100 years since Alois Alzheimer first described the devastating neurodegenerative disease that now bears his name, scientists have developed an increasingly sophisticated understanding of the brain. 

A novel mechanism that regulates activity in the brain, discovered by Weill Cornell Medicine investigators, may help explain the origins of one common type of dementia.

As brain disorders such as Alzheimer’s disease, autism and depression increase in frequency, the synergistic fields of neurology and psychiatry may illuminate important clues that can lead to innovative treatments for these conditions.